Literature DB >> 6372478

Extrinsic risk factors for pneumonia in the patient at high risk of infection.

F S Rhame, A J Streifel, J H Kersey, P B McGlave.   

Abstract

Most nosocomial pathogens cause pneumonia through the following sequence: transit to the patient on the hands of medical personnel or perhaps in food, proliferation in the nasopharynx, and subsequent pulmonary aspiration. There are three exceptional pathogens, each of particular concern as a cause of pneumonia in the immunocompromised patient, which follow atypical routes. Important recent advances in understanding these routes permit more rational preventive measures. This report examines the evidentiary basis for the following pathophysiolgic propositions about these three pathogens: Aspergillus, Pneumocystis carinii, and Legionella. Aspergillus spores are almost ubiquitous. Spore generation, except in very unusual circumstances, takes place outside the hospital. Most spores enter the hospital borne in air by infiltration or because of incomplete filtration. Air filtration systems of moderate efficiency remove Aspergillus spores. Nosocomial pulmonary and disseminated aspergillosis arises from inhalation of airborne spores. A nasopharygeal colonization intermediate step before pulmonary disease has not yet been solidly established. It is now firmly established that airborne Pneumocystic carinii transmission occurs between animals. Airborne acquisition probably occurs early in human life. However, in-hospital, person-to-person transmission has yet to be convincingly demonstrated. Most or all cases of pneumocystosis in adults are due to reactivation of endogenous pulmonary organisms. Intensive diagnostic efforts reveal that Legionella is a common cause of community-acquired and nosocomial pneumonia in hospitals where it had not previously been recognized. However, there are at least a few hospitals where it is an uncommon source of pneumonia. Several hospitals have demonstrated a temporal association between the presence of Legionella in hot water systems and nosocomial cases of Legionella pneumonia. The mechanism or mechanisms of transmission to the patient remain to be delineated. It is also not determined if all hospital hot water systems should be maintained Legionella free.

Entities:  

Mesh:

Year:  1984        PMID: 6372478     DOI: 10.1016/0002-9343(84)90243-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Invasive aspergillosis in immunosuppressed patients: potential hazard of hospital building work.

Authors:  A G Dewhurst; M J Cooper; S M Khan; A P Pallett; J R Dathan
Journal:  BMJ       Date:  1990-10-06

2.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

4.  Distribution, clearance, and mortality of environmental pseudomonads in mice upon intranasal exposure.

Authors:  S E George; M J Kohan; D A Whitehouse; J P Creason; C Y Kawanishi; R L Sherwood; L D Claxton
Journal:  Appl Environ Microbiol       Date:  1991-08       Impact factor: 4.792

5.  Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air.

Authors:  K Anderson; G Morris; H Kennedy; J Croall; J Michie; M D Richardson; B Gibson
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

6.  Invasive aspergillosis of the nose and paranasal sinuses in immunocompromised children.

Authors:  C Rotstein
Journal:  CMAJ       Date:  1988-08-15       Impact factor: 8.262

7.  Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies.

Authors:  G Todeschini; C Murari; R Bonesi; G Pizzolo; G Amaddi; A Ambrosetti; S Cerù; I Piacentini; N Martini; P Montresor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

Review 8.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 9.  Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment.

Authors:  T J Walsh; D M Dixon
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

10.  Model of recurrent pulmonary aspergillosis in rats.

Authors:  Y Niki; E M Bernard; F F Edwards; H J Schmitt; B Yu; D Armstrong
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.